Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.74 |
| ▸ | FNTB | P49356 | 12/20 | 0.74 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.73 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3099425 | 1.00 | FNTA (0.74) | FNTAFNTBPGGT1BGGPS1ALDH1A1 | |
| SCHEMBL3099416 | 1.00 | FNTA (0.74) | FNTAFNTBPGGT1BGGPS1ALDH1A1 | |
| SCHEMBL27449299 | 1.00 | FNTA (0.74) | FNTAFNTBPGGT1BGGPS1ALDH1A1 | |
| SCHEMBL1379697 | 0.98 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL1379703 | 0.98 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL23674223 | 0.98 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL2506806 | 0.98 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL18042467 | 0.98 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL812431 | 0.98 | FNTA (0.77) | FNTAFNTBPGGT1B | |
| SCHEMBL169443 | 0.98 | FNTA (0.77) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3737385-B1 | GLYCOSYLTRANSFERASE INHIBITORS | CALIFORNIA INST OF TECHN (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12570684-B2 | DPAGT1 inhibitors of capuramycin analogues and their antimigratory activities of solid tumors | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2026-03-10 | — | — | US | disclosed |
| WO-2025245227-A1 | BACTERIAL CELL WALL COMPONENTS AS PROBES FOR A LABEL-FREE BINDING ASSAY AND THE USE THEREOF | ACADEMIA SINICA (TW) | 2025-11-27 | — | — | WO | disclosed |
| US-20250092081-A1 | USE OF GLYCOSYLTRASNFERASE INHIBITORS FOR TREATING CANCER | CALIFORNIA INST OF TECHN (US) | 2025-03-20 | — | — | US | disclosed |
| US-12129272-B2 | Glycosyltransferase inhibitors | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2024-10-29 | — | — | US | disclosed |
| US-20240199677-A1 | GLYCOSYLTRANSFERASE INHIBITORS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2024-06-20 | — | — | US | disclosed |
| US-20230340006-A1 | DPAGT1 INHIBITORS OF CAPURAMYCIN ANALOGUES AND THEIR ANTIMIGRATORY ACTIVITIES OF SOLID TUMORS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-10-26 | — | — | US | disclosed |
| US-11597743-B2 | Glycosyltransferase inhibitors for treatment of solid tumors | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-03-07 | — | — | US | disclosed |
| US-20220162188-A1 | ISOPRENOIDS AND METHODS OF MAKING THEREOF | NORTH CAROLINA STATE UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162188-A1 | ISOPRENOIDS AND METHODS OF MAKING THEREOF | GGPS1, SQLE, FDPS | FNTA 14/4885FNTB 31/4885PGGT1B 261/4885 |
| US-12129272-B2 | Glycosyltransferase inhibitors | GALNT1, B4GALT1, GALNT2 | FNTA 34/4885FNTB 33/4885PGGT1B 96/4885 |
| US-20230340006-A1 | DPAGT1 INHIBITORS OF CAPURAMYCIN ANALOGUES AND THEIR ANTIMIGRATORY ACTIVITIES OF SOLID TUMORS | DPAGT1, DPM1, DIMT1 | FNTA 1063/4885FNTB 1311/4885PGGT1B 143/4885 |
| US-11597743-B2 | Glycosyltransferase inhibitors for treatment of solid tumors | DPAGT1, UGGT1, MAGT1 | FNTA 78/4885FNTB 95/4885PGGT1B 68/4885 |
| US-20240199677-A1 | GLYCOSYLTRANSFERASE INHIBITORS | GALNT1, B4GALT1, GALNT2 | FNTA 34/4885FNTB 33/4885PGGT1B 96/4885 |
| US-12570684-B2 | DPAGT1 inhibitors of capuramycin analogues and their antimigratory activities of solid tumors | DPAGT1, MAGT1, DAD1 | FNTA 273/4885FNTB 426/4885PGGT1B 583/4885 |
| US-20250092081-A1 | USE OF GLYCOSYLTRASNFERASE INHIBITORS FOR TREATING CANCER | ENGASE, GPI, ST6GAL1 | FNTA 333/4885FNTB 381/4885PGGT1B 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.